Current Patent Status for Flurbiprofen in Europe
Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation, has no active patents protecting its core compound in Europe. The original patents expired decades ago—typically in the 1980s for the molecule itself—allowing generic entry long before modern challenges became common. European Patent Office (EPO) records show no ongoing exclusivity for the base drug, with multiple generics available across EU markets.[1]
Why No Major Patent Challenges Exist
As an older drug discovered in the 1960s by Upjohn (now part of Pfizer), flurbiprofen's primary patents lapsed without significant opposition. Post-expiry, focus shifted to secondary patents on formulations (e.g., lozenges for sore throat like Strepfen) or combinations, but these face routine scrutiny under EU law. No high-profile EPO oppositions or nullity actions target flurbiprofen today, unlike newer NSAIDs. DrugPatentWatch confirms no listed European patents for flurbiprofen with active protection or disputes.[2]
Recent Formulation Patents and Minor Disputes
Some newer patents cover specific delivery methods, such as:
- EP 2 849 665 (expires 2034) for flurbiprofen axetil in acute pain, held by Kaken Pharmaceutical—filed in Japan but validated in Europe with no recorded challenges.[3]
- EP 1 579 838 (expired 2023) for oral spray formulations, which saw generic competition post-lapse without litigation.
Generic firms like Mylan and Sandoz market flurbiprofen freely, indicating weak barriers. The European Medicines Agency (EMA) lists over 20 authorized generics, underscoring expired core protection.[4]
How EU Patent Challenges Work for Old Drugs Like This
Under the European Patent Convention, third parties can oppose grants within 9 months at the EPO or seek revocation via national courts. For flurbiprofen, lack of novelty challenges stems from prior art (e.g., 1970s publications). Supplementary Protection Certificates (SPCs) extended some formulation patents to ~2025 max, but most ended without fights. Biosimilar-like generics entered seamlessly post-expiry.[5]
Comparison to Patent Battles for Similar NSAIDs
Unlike ibuprofen (ongoing SPC disputes in UK courts) or naproxen (challenges to combo patents), flurbiprofen avoids scrutiny due to age. Reckitt Benckiser defended Strepfen trademarks more than patents, with IP fights centering on branding, not molecule protection.[6]
Sources
[1] European Patent Register
[2] DrugPatentWatch.com
[3] EPO Espacenet - EP2849665
[4] EMA Medicines Database
[5] European Patent Convention Guidelines
[6] UK IPO Trademark Decisions